News
TVabp shortsABP ShortsVideos Podcast
X

Now, Cheapest Version Of Remdesivir Available At ₹ 2,800 Per Vial from Zydus Cadila

In June 2020, Zydus inked a non-exclusive agreement with Gilead Sciences Inc to manufacture and sell Remdesivir, which has been issued an emergency use to treat critical coronavirus patients.

Share:
New Delhi: Now, the cheapest version of Gilead Sciences' antiviral drug remdesivir in India to treat Covid-19 has been launched by Zydus Cadila and available at ₹ 2,800 ($37.44) per 100mg vial. Amid the reports of shortages at hospitals in view of the increasing cases of coronavirus in the country, Zydus has launched the Remdesivir version which will be sold under the brand name Remdac. The company will sell it to government and private hospitals treating Covid-19 patients, as per the company regulatory filing. Also Read: Coronavirus Vaccine | 'Robust Immunity' Induced By Pfizer-BioNTech Vaccine Candidate In Early-Phase Clinical Trial: Study In a statement, the drugmaker said, "The drug will be made available across India through the group’s strong distribution chain reaching out to government and private hospitals treating COVID patients. In June 2020, Zydus inked a non-exclusive agreement with Gilead Sciences Inc to manufacture and sell Remdesivir, the investigational drug, which has been issued an emergency use authorization by the US Food and Drug Administration (FDA) to treat critical patients infected with the novel coronavirus. Earlier in some Indian states officials had complained about supply issues, but a top executive at drugmaker Cipla told the business daily that the supplies were stabilising. The active pharmaceutical ingredients (API) for the drug has been developed and manufactured at the group’s API manufacturing facilities in Gujarat. The group’s plasmid DNA vaccine ZyCov-D is currently in Phase II of the Adaptive Phase I&II clinical trials. In India, Zydus emerges as the fifth company to launch a copy of the antiviral after pharma companies such as Hetero Labs, Cipla, Mylan NV and Jubilant Life Sciences. Officials in some Indian states had a few weeks ago complained of supply issues, but a top executive at drugmaker Cipla had earlier this week said the supplies were stabilising. The US firm Gilead has inked licensing agreements with Dr.Reddy's Laboratories and Syngene International for production of remdesivir for distribution in 127 countries, including India.

The country's coronavirus count reached 23,96,638 including 6,53,622 active cases, 16,95,982 discharged and 47,033 deaths.

Check out below Health Tools-
Calculate Your Body Mass Index ( BMI )

Calculate The Age Through Age Calculator

Published at : 13 Aug 2020 03:16 PM (IST) Tags: coronavirus drug covid-19 medicine Remdesivir drug zydus cadila
Follow Breaking News on abp LIVE for more latest stories and trending topics. Watch breaking news and top headlines online on abp News LIVE TV